From:
Sukie Crandall
Date: 2011-01-06 20:55:14 UTC
Subject: [ferrethealth] abstract
To: fhl <ferrethealth@yahoogroups.com>
The full paper is available for free at
http://jpet.aspetjournals.org/content/early/2011/01/04/jpet.110.173641.long
so may be useful for some vets dealing with ferrets
who have certain serious lung issues.
BEGIN QUOTED ABSTRACT
J Pharmacol Exp Ther. 2011 Jan 4. [Epub ahead of print]
In Vivo Characterisation of GSK256066, A High Affinity Inhaled=20
Phosphodiesterase 4 Inhibitor.
Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE,=20
Knowles RG.
1 GlaxoSmithKline;
Abstract
Oral PDE4 inhibitors have demonstrated clinical efficacy in chronic=20
obstructive pulmonary disease and asthma. Pre clinical and clinical=20
investigation of inhaled PDE4 inhibitors is ongoing. GSK256066 is an=20
exceptionally high affinity and selective inhibitor of PDE4 designed=20
for inhaled delivery. The aim of these studies was to investigate the=20
potency, duration of action and therapeutic index of GSK256066 in=20
animal models of pulmonary inflammation. The effects of=20
intratracheally administered GSK256066 were investigated in rat=20
lipopolysaccharide (LPS) and ovalbumin induced models of acute,=20
pulmonary inflammation. In some studies, fluticasone propionate (FP)=20
was included as a comparator. The Therapeutic Index (anti-inflammatory=20
effect versus emesis) of GSK256066 was studied in ferrets where acute=20
pulmonary inflammation was induced with inhaled LPS. In rats,=20
GSK256066 and FP caused significant (p<0.05) inhibition of LPS-induced=20
pulmonary neutrophilia. The duration of action of GSK256066 at 10 x=20
ED50 dose (10=CE=BCg/kg) was 12h. GSK256066 and FP also inhibited LPS-
induced increases in exhaled nitric oxide (ED50 35 =C2=B5g/kg & 92 =CE=BCg/=
kg=20
respectively). In addition, GSK256066 inhibited pulmonary eosinophilia=20
in rats exposed to ovalbumin (ED50 0.4 =CE=BCg/kg). In ferrets, inhaled =
GSK256066 inhibited LPS-induced pulmonary neutrophilia (ED50 18 =CE=BCg/kg)=
=20
and no emetic episodes were observed. Thus, GSK256066 may have an=20
improved therapeutic index compared to oral PDE4 inhibitors e.g.=20
cilomilast and roflumilast. In summary, GSK256066 demonstrates potent=20
and long-lasting anti-inflammatory effects in animal models of=20
pulmonary inflammation and does not induce emetic episodes in ferrets.=20
GSK256066 has potential as an inhaled therapeutic for the treatment of=20
asthma and Chronic Obstructive Pulmonary Disease.
PMID: 21205924 [PubMed - as supplied by publisher]
END QUOTED ABSTRACT
Sukie (not a vet)
Recommended ferret health links:
http://pets.groups.yahoo.com/group/ferrethealth/
http://ferrethealth.org/archive/
http://www.afip.org/ferrets/index.html
http://www.miamiferret.org/
http://www.ferrethealth.msu.edu/
http://www.ferretcongress.org/
http://www.trifl.org/index.shtml
http://homepage.mac.com/sukie/sukiesferretlinks.html
all ferret topics:
http://listserv.ferretmailinglist.org/archives/ferret-search.html
"All hail the procrastinators for they shall rule the world tomorrow."
(2010, Steve Crandall)
------------------------------------
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/ferrethealth/
<*> Your email settings:
Individual Email | Traditional
<*> To change settings online go to:
http://groups.yahoo.com/group/ferrethealth/join
(Yahoo! ID required)
<*> To change settings via email:
ferrethealth-digest@yahoogroups.com
ferrethealth-fullfeatured@yahoogroups.com
<*> To unsubscribe from this group, send an email to:
ferrethealth-unsubscribe@yahoogroups.com
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/